Literature DB >> 21195298

Cellular therapy for fanconi anemia: the past, present, and future.

Margaret L MacMillan1, Mark R Hughes, Suneet Agarwal, George Q Daley.   

Abstract

Allogeneic hematopoietic cell transplantation (HCT) remains the only proven curative therapy for the hematologic manifestation of Fanconi anemia (FA). Over the past 2 decades, major advances have been made such that transplant outcomes have markedly improved. With the development of in vitro fertilization and preimplantation genetic diagnosis, HLA-matched sibling donor umbilical blood transplantation may be an option for more patients with FA. Recently, the use of pluripotent stem cells has been explored as a novel approach to model the hematopoietic developmental defects in FA, and to provide a potential source of autologous stem cells that can be genetically manipulated and used to generate corrected hematopoietic progenitors. Copyright Â
© 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21195298     DOI: 10.1016/j.bbmt.2010.11.027

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  11 in total

Review 1.  Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines.

Authors:  K Scheckenbach; M Wagenmann; M Freund; J Schipper; H Hanenberg
Journal:  Klin Padiatr       Date:  2012-04-13       Impact factor: 1.349

Review 2.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

3.  Interleukin 8/KC enhances G-CSF induced hematopoietic stem/progenitor cell mobilization in Fancg deficient mice.

Authors:  Yan Li; Wen Xing; Yong-Zheng He; Shi Chen; Steven D Rhodes; Jin Yuan; Yuan Zhou; Jun Shi; Jie Bai; Feng-Kui Zhang; Wei-Ping Yuan; Tao Cheng; Ming-Jiang Xu; Feng-Chun Yang
Journal:  Stem Cell Investig       Date:  2014-10-31

Review 4.  Molecular pathogenesis and clinical management of Fanconi anemia.

Authors:  Younghoon Kee; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

5.  Low-dose irradiation prior to bone marrow transplantation results in ATM activation and increased lethality in Atm-deficient mice.

Authors:  J Pietzner; B M Merscher; P C Baer; R P Duecker; O Eickmeier; D Fußbroich; P Bader; D Del Turco; R Henschler; S Zielen; R Schubert
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

Review 6.  Strategies for more rapid translation of cellular therapies for children: a US perspective.

Authors:  Rosa Sanchez; Leslie E Silberstein; Robert W Lindblad; Lisbeth A Welniak; Traci Heath Mondoro; John E Wagner
Journal:  Pediatrics       Date:  2013-07-08       Impact factor: 7.124

Review 7.  The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma.

Authors:  Lindsey E Romick-Rosendale; Vivian W Y Lui; Jennifer R Grandis; Susanne I Wells
Journal:  Mutat Res       Date:  2013-01-17       Impact factor: 2.433

Review 8.  Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Cancer Surveillance in Fanconi Anemia.

Authors:  Sharon A Savage; Michael F Walsh
Journal:  Hematol Oncol Clin North Am       Date:  2018-08       Impact factor: 3.722

9.  Mesenchymal COX2-PG secretome engages NR4A-WNT signalling axis in haematopoietic progenitors to suppress anti-leukaemia immunity.

Authors:  Limei Wu; Surya Amarachintha; Jian Xu; Frank Oley; Wei Du
Journal:  Br J Haematol       Date:  2018-08-14       Impact factor: 6.998

10.  Disrupted Signaling through the Fanconi Anemia Pathway Leads to Dysfunctional Hematopoietic Stem Cell Biology: Underlying Mechanisms and Potential Therapeutic Strategies.

Authors:  Anja Geiselhart; Amelie Lier; Dagmar Walter; Michael D Milsom
Journal:  Anemia       Date:  2012-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.